Official Title
Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial
Brief Summary

The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.

Detailed Description

We will evaluate the effect of aspirin (150mg once daily), losartan (100mg once daily), and
simvastatin (80mg once daily) in patients with COVID-19 infection.

Eligible patients will be randomly allocated to one of eight study arms (aspirin only;
losartan only; simvastatin only; aspirin and losartan; aspirin and simvastatin; losartan and
simvastatin; aspirin, losartan and simvastatin; standard care only). Trial treatments are
given in addition to the usual standard of care at the study hospital.

Treatment will be started as soon as possible after randomisation and will continue until
death, discharge or 28 days after randomisation, whichever occurs first.


Drug: Aspirin

Aspirin 150mg

Drug: Losartan

Losartan 100mg

Drug: Simvastatin

Simvastatin 80mg

Eligibility Criteria

Inclusion Criteria:

- Adults age 40 years and older

- with suspected or confirmed acute COVID-19 infection. Acute COVID-19 infection is
suspected in the presence of a fever and at least one symptom of respiratory disease
e.g. cough, difficulty breathing, signs of hypoxia. The clinician may suspect COVID-19
infection if i) the patient lives in or has recently travelled to an area with
COVID-19 transmission; ii) the patient had recent contact with a confirmed or probable
COVID-19 case, or iii) no alternative diagnosis fully explains the clinical

- requiring hospitalisation

Exclusion Criteria:

- Women known to be pregnant

- Patients hospitalised without symptoms of acute COVID-19 infection should not be
recruited even if they test positive for COVID-19

- Patients already receiving mechanical ventilation

- Patients with a definite indication or contraindication for any of the trial

- Patients who are very severely frail (completely dependent and approaching end of life
who typically they could not recover even from a mild illness) or terminally ill
should not be recruited.

Eligibility Gender
Eligibility Age
Minimum: 40 Years ~ Maximum: N/A

University College Hospital
Ibadan, Oyo, Nigeria

Shifa Tameer-e-Millat University
Rawalpindi, Pakistan

London School of Hygiene and Tropical Medicine
NCT Number
Adult respiratory distress syndrome
Myocardial infarction
MeSH Terms